Fairmont Hotel Vancouver Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2005



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Meeting the Challenges of Drug Discovery (A6)


Organizer(s) Stephen W. Fesik and Michael D. Varney
January 15—20, 2005
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Abstract Deadline: Sep 20, 2004
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Nov 15, 2004

Sponsored by Iconix Pharmaceuticals, Inc. and ICOS Corporation

Summary of Meeting:
The drug discovery process is difficult, challenging, costly, and often leads to failure. Nevertheless, it is critical that we continue to discover new drugs to meet the many unmet medical needs. To reduce the costs and improve the success of drug discovery and development, new technologies and strategies have been developed. To aid in the target identification and validation steps of the drug discovery process, RNAi technology for gene knockdown is playing an important role along with large-scale gene knockouts in animals. Novel screening approaches, high-throughput synthesis, iterative structure-based design, and in vitro toxicity assays are aiding lead identification and optimization. In addition, approaches are being developed for identifying and utilizing biomarkers in clinical trials to improve the success of drug approval. Advances have also been made in the discovery of biomolecules for the treatment of disease. In this Keystone Symposium, approaches for streamlining and improving drug discovery and development will be discussed that include enabling technologies to aid in target identification/validation and lead identification/optimization, strategies for discovering and applying DNA, RNA, and protein biomarkers in pre-clinical studies and clinical trials, and the use of biologicals to treat disease. In addition, success stories on new drug candidates will be presented.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SATURDAY, JANUARY 15

15:00—19:30
Registration

BC Foyer
18:30—19:30
Refreshments

BC Foyer
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

British
Leslie J. Browne, Senesco Technologies, Inc., USA
The Future of Drug Discovery - Where Do We Go From Here?


SUNDAY, JANUARY 16

07:00—08:00
Breakfast

Columbia
08:00—11:00
Selecting the Right Targets
Meeting has ended...abstracts no longer viewable online.

British
* Brian Zambrowicz, Regeneron, USA
Genetic Modeling of Chemical Antagonists: Genome-Scale Discovery of Drug Targets by in vivo Functional Analysis

Stewart Noble, Kalypsys, Inc., USA
Driving Target Selection by Compound Profiling

Frank Koentgen, Ozgene Pty Ltd, Australia
Use of RNAi for Gene Knockdown in Mice

William L. Wishart, Novartis Institutes for BioMedical Research, Switzerland
RNAi/Antisense Based Drug Target Validation In Vivo.

09:20—09:40
Coffee Break

BC Foyer
11:00—13:00
Poster Setup

Columbia
13:00—22:00
Poster Viewing

Columbia
16:30—17:00
Coffee & Snacks Available

BC Foyer
17:00—19:00
Speeding up the Drug Discovery Process
Meeting has ended...abstracts no longer viewable online.

British
* Stephen K. Burley, Rutgers University, USA
Structure-Guided Drug Discovery Using Fragment-Based Lead Identification/Lead Optimization

David J. Burns, Abbott Laboratories, USA
HTS for Expediting Drug Discovery

Gerhard Klebe, Philipps University Marburg, Germany
Virtual Ligand Screening: Successes and Limitations

19:00—20:00
Social Hour

Columbia
19:30—22:00
Poster Session 1

Columbia

MONDAY, JANUARY 17

07:00—08:00
Breakfast

Columbia
08:00—11:00
Early Detection of Toxicity
Meeting has ended...abstracts no longer viewable online.

British
* Stephen K. Durham, Bristol-Myers Squibb Company, USA
Addressing Drug Safety Liabilities Early in the Drug Discovery Process

Kyle L. Kolaja, Celgene, USA
The Use of a Chemogenomic Reference Database to Optimize Drug Candidate Selection

James M. McKim, Jr., CeeTox, USA
Incorporating in vitro Toxicity Data into Early Drug Discovery

Dale E. Johnson, Emiliem, Inc., USA
Computational Approaches for the Prediction of Drug-Induced Toxicity

09:20—09:40
Coffee Break

BC Foyer
11:00—13:00
Poster Setup

Columbia
13:00—22:00
Poster Viewing

Columbia
16:30—17:00
Coffee & Snacks Available

BC Foyer
17:00—19:00
More Predictive Animal Models
Meeting has ended...abstracts no longer viewable online.

British
* Chand Khanna, National Cancer Institute, National Institutes of Health, USA
A Novel and Integrated Approach towards Cancer Drug Development: Evaluation of Early Clinical Agents in Companion Animals with Cancer

Irene Tracey, University of Oxford, UK
Functional Magnetic Resonance Imaging of Pain Processing in Humans - Beyond Animal Models

Murray O. Robinson, Molquant, Inc., USA
Inducible Tumor Models for Target Identification and Drug Discovery

19:00—20:00
Social Hour

Columbia
19:30—22:00
Poster Session 2

Columbia

TUESDAY, JANUARY 18

07:00—08:00
Breakfast

Columbia
08:00—11:00
Useful Tools for Decision Making in the Clinic
Meeting has ended...abstracts no longer viewable online.

British
* Todd R. Golub, Broad Institute, USA
Genomic Information and Cancer

Roger G. Ulrich, RUC Pharmaceutical Development Specialists, USA
Improving Drug Development through Molecular Profiling

Samir Hanash, Fred Hutchinson Cancer Research Center, USA
Contributions of Proteomics to the Drug Discovery Process

09:20—09:40
Coffee Break

BC Foyer
16:30—17:00
Coffee & Snacks Available

BC Foyer
17:00—19:00
Biologics
Meeting has ended...abstracts no longer viewable online.

British
* C. Frank Bennett, Ionis Pharmaceuticals, Inc., USA
Progress in Antisense Oligonucleotide Based Therapeutics

Napoleone Ferrara, University of California, San Diego, USA
Antibodies Against VEGF

John M. Maraganore, Alnylam Pharmaceuticals Inc., USA
Turning siRNA's into Drugs

19:00—20:00
Social Hour

Columbia

WEDNESDAY, JANUARY 19

07:00—08:00
Breakfast

Columbia
08:00—11:00
New Drug Candidates
Meeting has ended...abstracts no longer viewable online.

British
* Stephen W. Kaldor, Quanticel Pharmaceuticals, USA
DPP IV Antagonists

Daria J. Hazuda, Merck Research Laboratories, USA
Pyrophosphate Mimetics: A Mechanism Based Approach to Antiviral Drug Discovery

John A. Thomson, Vertex Pharmaceuticals Incorporated, USA
Mechanism-Based Design of Synergistic Therapeutics for Hepatitis C

Joel Hayflick, , USA
PI3 Kinase delta Inhibitors for the Treatment of Cancer and Autoimmune Diseases

09:20—09:40
Coffee Break

BC Foyer
16:30—17:00
Coffee & Snacks Available

BC Foyer
17:00—19:00
Hot Breaking Stories
Meeting has ended...abstracts no longer viewable online.

British
* Steven Elmore, Abbott Laboratories, USA
Bcl-2 Family Inhibitors for the Treatment of Cancer

Prasanna G. Alluri, University of Minnesota School of Medicine, USA
Short Talk: A Chemical Genetic Approach to Regulation of Gene Expression

Marcel Hoffmann, Crystallics, Netherlands
Short Talk: Drug Targets with Functional Diseas Relevance Discovered with Arrayed Adenoviral siRNA Libraries

John Keirn Westwick, Odyssey Thera, Inc., USA
Short Talk: Defining Drug Mechanism of Action within Human Cellular Networks

19:00—20:00
Social Hour

Columbia
20:00—23:00
Entertainment

Columbia

THURSDAY, JANUARY 20

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge additional support for this conference from:

Cell Signaling Technology, Inc. Iconix Biosciences, Inc.
ICOS Corporation Novartis Institutes for BioMedical Research

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Abbott Laboratories


Agouron Pharmaceuticals, Inc.


Alnylam Pharmaceuticals, Inc.


AVEO Pharmaceuticals, Inc.


Bristol-Myers Squibb Company


CeeTox Inc.


Chiron Corporation


Galapagos NV


Genentech, Inc.


Iconix Biosciences, Inc.


ICOS Corporation


Isis Pharmaceuticals, Inc.


Kalypsys, Inc.


Lexicon Pharmaceuticals Inc.


Merck Research Laboratories


Novartis Institutes for BioMedical Research


Odyssey Thera


Ozgene Pty Ltd


SGX Pharmaceuticals


Syrrx, Inc.


Vertex Pharmaceuticals Incorporated


Merck Research Laboratories


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676